Clinical Trial

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-08; most recent amendment 2026-03-10.
Trial Details
NCT Number NCT06976476
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Multiple Myeloma, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired
Enrollment 100 participants
Start Date 2025-05-08
Primary Completion 2029-05-08 (estimated)
Study Completion 2029-05-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-11